301 related articles for article (PubMed ID: 33311453)
1. Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer.
Tan X; Zhang Z; Liu P; Yao H; Shen L; Tong JS
Cell Death Dis; 2020 Dec; 11(12):1061. PubMed ID: 33311453
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis.
Chen D; Wei L; Yu J; Zhang L
Clin Cancer Res; 2014 Jul; 20(13):3472-84. PubMed ID: 24763611
[TBL] [Abstract][Full Text] [Related]
3. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.
Julia E; Salles G
Future Oncol; 2021 Jun; 17(17):2127-2140. PubMed ID: 33709777
[TBL] [Abstract][Full Text] [Related]
4. The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment.
Yuan H; Nishikori M; Otsuka Y; Arima H; Kitawaki T; Takaori-Kondo A
Cancer Sci; 2021 Nov; 112(11):4604-4616. PubMed ID: 34449935
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies.
Qi L; Lindsay H; Kogiso M; Du Y; Braun FK; Zhang H; Guo L; Zhao S; Injac SG; Baxter PA; Su JM; Xiao S; Erickson SW; Earley EJ; Teicher B; Smith MA; Li XN
Lab Invest; 2022 Feb; 102(2):185-193. PubMed ID: 34802040
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.
Yang S; Zhang X; Qu H; Qu B; Yin X; Zhao H
Cancer Gene Ther; 2020 May; 27(5):368-377. PubMed ID: 31182761
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology and pharmacokinetics of tazemetostat.
Orleni M; Beumer JH
Cancer Chemother Pharmacol; 2024 May; 93(5):509-517. PubMed ID: 38520556
[TBL] [Abstract][Full Text] [Related]
8. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF
Fu H; Cheng L; Sa R; Jin Y; Chen L
J Cell Mol Med; 2020 Mar; 24(6):3336-3345. PubMed ID: 31970877
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids.
Mola S; Pinton G; Erreni M; Corazzari M; De Andrea M; Grolla AA; Martini V; Moro L; Porta C
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922336
[TBL] [Abstract][Full Text] [Related]
10. Tazemetostat for advanced epithelioid sarcoma: current status and future perspectives.
Simeone N; Frezza AM; Zaffaroni N; Stacchiotti S
Future Oncol; 2021 Apr; 17(10):1253-1263. PubMed ID: 33289402
[TBL] [Abstract][Full Text] [Related]
11. Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program.
Kurmasheva RT; Sammons M; Favours E; Wu J; Kurmashev D; Cosmopoulos K; Keilhack H; Klaus CR; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27555605
[TBL] [Abstract][Full Text] [Related]
12. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
13. Idelalisib induces PUMA-dependent apoptosis in colon cancer cells.
Yang S; Zhu Z; Zhang X; Zhang N; Yao Z
Oncotarget; 2017 Jan; 8(4):6102-6113. PubMed ID: 28008149
[TBL] [Abstract][Full Text] [Related]
14. Gypenosides Synergistically Enhances the Anti-Tumor Effect of 5-Fluorouracil on Colorectal Cancer In Vitro and In Vivo: A Role for Oxidative Stress-Mediated DNA Damage and p53 Activation.
Kong L; Wang X; Zhang K; Yuan W; Yang Q; Fan J; Wang P; Liu Q
PLoS One; 2015; 10(9):e0137888. PubMed ID: 26368019
[TBL] [Abstract][Full Text] [Related]
15. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
[TBL] [Abstract][Full Text] [Related]
16. Purified vitexin compound 1, a new neolignan isolated compound, promotes PUMA-dependent apoptosis in colorectal cancer.
Chen J; Zhong J; Liu Y; Huang Y; Luo F; Zhou Y; Pan X; Cao S; Zhang L; Zhang Y; Wang J
Cancer Med; 2018 Dec; 7(12):6158-6169. PubMed ID: 30402948
[TBL] [Abstract][Full Text] [Related]
17. Copanlisib promotes growth inhibition and apoptosis by modulating the AKT/FoxO3a/PUMA axis in colorectal cancer.
Yan J; Yang S; Tian H; Zhang Y; Zhao H
Cell Death Dis; 2020 Nov; 11(11):943. PubMed ID: 33139695
[TBL] [Abstract][Full Text] [Related]
18. PUMA mediates the combinational therapy of 5-FU and NVP-BEZ235 in colon cancer.
Wang H; Zhang L; Yang X; Jin Y; Pei S; Zhang D; Zhang H; Zhou B; Zhang Y; Lin D
Oncotarget; 2015 Jun; 6(16):14385-98. PubMed ID: 25965911
[TBL] [Abstract][Full Text] [Related]
19. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
[No Abstract] [Full Text] [Related]
20. Crizotinib induces PUMA-dependent apoptosis in colon cancer cells.
Zheng X; He K; Zhang L; Yu J
Mol Cancer Ther; 2013 May; 12(5):777-86. PubMed ID: 23427294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]